As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > BUSINESS
BUSINESS
- Takecab Most Heavily Pitched Drug in January: Anterio
March 11, 2016
- Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
- Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
March 9, 2016
- Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
March 8, 2016
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
- NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
March 7, 2016
- Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
March 4, 2016
- Teva Pharma Japan Voluntarily Recalling 7 Products
March 3, 2016
- Public Knowledge-Based Application Filed for Xeloda as Adjuvant Chemotherapy for Rectal Cancer: Chugai
March 3, 2016
- Pfizer Japan Chief Frets Possible Decline in Foreign Investments amid Anti-Innovation Drug Policies
March 3, 2016
- Pfizer’s Japan Sales Tick Up 2% in FY2015
March 3, 2016
- Takeda and Mizuho Medy Tie Up for Marketing of OTC Pregnancy Test Kit, Ovulation Predictor Kit
March 3, 2016
- Eisai Board OKs Hajime Shimizu as 1st President of EA Pharma
March 2, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…